



EY Entrepreneur of the year-2013



FROST & SULLIVAN 2013 Best Practices-2013



Business today/YES bank Excellence Awards-2013



Date: 4th May, 2022

To BSE Limited Phiroze Jeejeebhoy Towers Dalal Street Mumbai- 400001	To National Stock Exchange of India Limited Exchange Plaza Bandra Kurla Complex Bandra (E) Mumbai-400051
Security Code: 540596	Symbol: ERIS

SUBJECT: INTIMATION UNDER REGULATION 30 AND OTHER APPLICABLE REGULATIONS OF SECURITIES AND EXCHANGE BOARD OF INDIA (LISTING OBLIGATIONS AND DISCLOSURE REQUIREMENTS) REGULATIONS, 2015

Dear Sir/Madam,

In accordance requirement of regulations 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Para A (1) of Part A of Schedule III and SEBI Circular CIR/CFD/CMD/4/2015 dated September 09, 2015, details attached herein may be taken on record

The details of the same will be uploaded on the website of the Company.

Thanking You,

For Eris Lifesciences Limited





Milind Talegaonkar
Company Secretary & Compliance Officer
Membership No: A26493

Encl: As above

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867



Annexure I

Acquisition(s)(including agreement to acquire), Scheme of Arrangement (amalgamation/ merger/ demerger/restructuring), or sale or disposal of any unit(s), division(s) or subsidiary of the listed entity or any other restructuring:

Acquisition (including agreement to acquire):		
a)	Name of the target entity, details in brief such as size, turnover etc.	OAKNET HEALTHCARE PRIVATE LIMITED <i>(as per clause j below)</i>
b)	whether the acquisition would fall within related party transaction(s) and whether the promoter/ promoter group/ group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "arms length";	No
c)	industry to which the entity being acquired belongs;	Pharmaceuticals
d)	Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity)	Acquisition facilitates the entry of Eris into the Dermatology segment in the following manner: <ul style="list-style-type: none"> • Expansion of the portfolio • Increased market reach and penetration • Improved segment ranking
e)	Brief details of any governmental or regulatory approvals required for the acquisition	None
f)	Indicative time period for completion of the acquisition	End of May 2022
g)	nature of consideration -whether cash consideration or share swap and details of the same;	Cash Consideration
h)	cost of acquisition or the price at which the shares are acquired	INR 650 crores

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867



EY Entrepreneur of the year-2013



FROST & SULLIVAN Best Practices-2013



Business today/YES bank Excellence Awards-2013



i)	Percentage of shareholding / control acquired and / or number of shares acquired;	100% Shareholding						
j)	brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	<p><u>Product Line:</u> Dermatology, Gynecology, Pain Management, Nutritional, Cardiology & Diabetes</p> <p><u>Date of Incorporation:</u> 08-08-2011</p> <p><u>History of last 3 years Turnover:</u></p> <table border="1" data-bbox="868 683 1528 801"> <tr> <td>FY 2020-21</td> <td>185.75 cr</td> </tr> <tr> <td>FY 2019-20</td> <td>191.52 cr</td> </tr> <tr> <td>FY 2018-19</td> <td>163.49 cr</td> </tr> </table> <p><u>Country in which the acquired entity has presence:</u> India</p>	FY 2020-21	185.75 cr	FY 2019-20	191.52 cr	FY 2018-19	163.49 cr
FY 2020-21	185.75 cr							
FY 2019-20	191.52 cr							
FY 2018-19	163.49 cr							

Registered & Corporate Office:

Shivarth Ambit, Plot No. 142/2, Ramdas Road, Off SBR, Near Swati Bungalows, Bodakdev, Ahmedabad – 380054
 Phone: +91-79-69661000/1001 • Email: eris@erislifesciences.com • Web Site: www.eris.co.in • CIN: L24232GJ2007PLC049867